Exhibit 10.46

 

EXECUTION COPY

 

***Text Omitted and Filed Separately

with the Securities and Exchange Commission.

Confidential Treatment Requested

Under 17 C.F.R. Sections 200.80(b)(4)
and 240.24b-2

 

AMENDMENT TO THE COMMERCIAL SUPPLY AGREEMENT

 

THIS AMENDMENT TO THE COMMERCIAL SUPPLY AGREEMENT (the “Amendment”) is made and
entered into effective as of December 8, 2008 (the “Amendment Date”), by and
between Amylin Pharmaceuticals, Inc. (“Amylin”) and Baxter Pharmaceutical
Solutions LLC (“Baxter”). Capitalized terms used in this Amendment that are not
otherwise defined herein shall have the meanings ascribed to such terms in the
Agreement (as defined herein).

 

WHEREAS, effective February 14, 2005, Amylin and Baxter entered into that
certain Commercial Supply Agreement (the “Agreement”) wherein Baxter agreed to
produce the Exenatide BID Product for Amylin pursuant to the terms and
conditions contained therein; and

 

WHEREAS, Amylin and Baxter desire to amend the Agreement as set forth herein
with respect to Amylin’s Annual Obligation.

 

NOW, THEREFORE, Amylin and Baxter agree as follows:

 

As of the Amendment Date, Amylin and Baxter agree that Exhibit F, as attached to
the Agreement prior to the Amendment Date, shall be deleted and replaced with
Exhibit F-1, attached to this Amendment.

 

The other provisions of the Agreement, not amended by this Amendment, remain in
full force and effect.  This Amendment may be executed in counterparts and all
such counterparts shall be treated as one and the same document.

 

IN WITNESS WHEREOF, Amylin and Baxter have executed this Amendment as of the
date first above written.

 

AMYLIN PHARMACEUTICALS, INC.

BAXTER PHARMACEUTICAL SOLUTIONS LLC

 

 

By:

/S/ PAUL MARSHALL

 

By:  

/S/ BRIK V. EYRE

Name:

Paul Marshall

 

Name:

Brik V. Eyre

Title:

Vice President, Operations

 

Title:

General Manager

Date:

01/07/2009

 

Date:

01/12/2009

 

--------------------------------------------------------------------------------

 

Exhibit F-1

 

Annual Obligation

 

YEAR

 

ANNUAL OBLIGATION

First calendar year following Regulatory Approval (2006)

 

[***]

Second calendar year following Regulatory Approval (2007)

 

[***]

Third calendar year following Regulatory Approval (2008)

 

[***]

Fourth calendar year following Regulatory Approval (2009)

 

[***]

Fifth calendar year following Regulatory Approval (2010)

 

[***]

Sixth calendar year following Regulatory Approval (2011)

 

[***]

 

***Confidential Treatment Requested

 

--------------------------------------------------------------------------------